Shopping Cart 0
Cart Subtotal
USD 0

U.S. Stem Cell Inc (USRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company's lead product MyoCell, is designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem Cell is headquartered in Sunrise, Florida, the US.

U.S. Stem Cell Inc (USRM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12

Private Equity 13

General American Capital to Invest up to USD5 Million in US Stem Cell 13

Partnerships 14

Bioheart Forms Joint Venture with Walter Bell 14

Licensing Agreements 15

Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15

Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16

Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17

Debt Offering 18

U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18

U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19

U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20

U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21

U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22

U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23

U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24

U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25

U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26

U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27

Acquisition 28

Bioheart to Acquire Pavillion Scientific 28

Bioheart to Invest in Ascyrus Medical 29

U.S. Stem Cell Inc-Key Competitors 30

U.S. Stem Cell Inc-Key Employees 31

U.S. Stem Cell Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Joint Venture 32

Recent Developments 33

Financial Announcements 33

Nov 07, 2018: USRM posts 25% nine month revenue increase from 3Q 2017 33

Aug 08, 2018: USRM posts profitable results for second quarter 2018 34

May 09, 2018: U.S. Stem Cell Reports First Quarter Results 35

Apr 16, 2018: USRM Reports 2017 Financial Results 36

Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company's History 37

Corporate Communications 38

Sep 11, 2018: USRM hires senior VP of US & international sales 38

Legal and Regulatory 39

Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 39

Product News 40

Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 40

Other Significant Developments 42

Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 42

Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 43

Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

U.S. Stem Cell Inc, Deals By Therapy Area, 2012 to YTD 2018 9

U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12

General American Capital to Invest up to USD5 Million in US Stem Cell 13

Bioheart Forms Joint Venture with Walter Bell 14

Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15

Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16

Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17

U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18

U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19

U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20

U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21

U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22

U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23

U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24

U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25

U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26

U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27

Bioheart to Acquire Pavillion Scientific 28

Bioheart to Invest in Ascyrus Medical 29

U.S. Stem Cell Inc, Key Competitors 30

U.S. Stem Cell Inc, Key Employees 31

U.S. Stem Cell Inc, Joint Venture 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

U.S. Stem Cell Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.